Federal reforms will never "fix" the flaws of the pharmaceutical drug system; instead, sponsors need to flex their clout and begin to take full advantage of the power they already possess. (Graphic by Chris Nicholls)
Once again, Congress is attempting to deal legislatively with the lack of transparency in pharmaceutical drug pricing. But most of the focus continues to be on Medicare drug policies, with true reform eluding the commercial/employer-sponsored marketplace.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
